Table 3.
Methylation frequency of two-gene panel (ADAMTS1 and/or BNC1) vs frequency of CA 19-9 elevation in different stages of pancreatic ductal adenocarcinoma
| Patients | Stage I (%) | Stage IIA (%) | Stage IIB (%) | Stages III–IV (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Positive/total | Positive (%) | Positive/total | Positive (%) | Positive/total | Positive (%) | Positive/total | Positive (%) | |
| ADAMTS1 | 7/8 | 87.5 | 7/9 | 77.8 | 18/20 | 90 | 2/2 | 100 |
| BNC1 | 5/8 | 62.5 | 5/9 | 55.6 | 13/20 | 65 | 2/2 | 100 |
| ADAMTS1 and/or BNC1 | 8/8 | 100 | 8/9 | 88.9 | 20/20 | 100 | 2/2 | 100 |
| CA 19-9 (n = 34)* | 4/7 | 57.1 | 4/9 | 44.4 | 11/17 | 64.7 | 0/1 | 0 |
| ADAMTS1 and/or BNC1 + CA 19-9 | 8/8 | 100 | 8/9 | 88.9 | 20/20 | 100 | 2/2 | 100 |
*Missing two CA 19-9 values, so % out of total recorded CA 19-9 values for each stage